| P50 | author | Anthony Atala | Q4772039 |
| P2093 | author name string | M R Freeman | |
| | M Johnson | |
| | M Kaefer | |
| | M Klagsbrun | |
| | S Soker | |
| P2860 | cites work | Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor | Q24294262 |
| | Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family | Q24303496 |
| | Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 |
| | Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor | Q24321564 |
| | Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor | Q24323249 |
| | Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 | Q24323317 |
| | The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 |
| | Signaling via vascular endothelial growth factor receptors | Q28139029 |
| | VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms | Q28141270 |
| | A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF | Q28646512 |
| | Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 |
| | Mechanisms of angiogenesis | Q29547485 |
| | Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene | Q29547732 |
| | Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele | Q29547733 |
| | Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 |
| | Vascular endothelial growth factor (VEGF) and its receptors | Q29615390 |
| | The biology of vascular endothelial growth factor | Q29615946 |
| | Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis | Q29617644 |
| | VEGFs, receptors and angiogenesis | Q33644265 |
| | Molecular angiogenesis | Q33696723 |
| | Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins | Q33775844 |
| | Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis | Q33900066 |
| | Vasculogenesis | Q34387300 |
| | Flk-1 as a target for tumor growth inhibition. | Q34392604 |
| | Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma | Q35833169 |
| | Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels | Q36230478 |
| | Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain | Q38360579 |
| | Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting | Q38470808 |
| | CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy | Q38471453 |
| | Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis | Q40377374 |
| | Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects | Q40922411 |
| | Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor | Q40959138 |
| | Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model | Q40972823 |
| | Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. | Q41114712 |
| | Angiogenesis and angiogenesis inhibition: an overview | Q41322520 |
| | Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. | Q41360117 |
| | Culture of a prostatic cell line in basement membrane gels results in an enhancement of malignant properties and constitutive alterations in gene expression | Q41491482 |
| | VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor | Q41505525 |
| | Advances in angiogenesis research: relevance to urological oncology | Q41614316 |
| | Angiogenesis and tumor metastasis | Q41724143 |
| | Angiogenesis and vasculogenesis in treatment of cardiovascular disease. | Q41942219 |
| | Vascular endothelial growth factor induces the disorganization of actin stress fibers accompanied by protein tyrosine phosphorylation and morphological change in Balb/C3T3 cells | Q42068036 |
| | Expression of vascular endothelial growth factor receptors in human prostate cancer | Q42477154 |
| | Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. | Q51089819 |
| | Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. | Q53407943 |
| | An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer . preliminary results and therapeutic implications. | Q54118091 |
| | Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis | Q55482573 |
| | The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities | Q59261168 |
| | Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer | Q60156367 |
| | Vascular permeability factor, an endothelial cell mitogen related to PDGF | Q69116052 |
| | Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals | Q69628302 |
| | Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors | Q70575554 |
| | Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity | Q71608229 |
| | Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms | Q71656434 |
| | Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing | Q72259824 |
| | Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor | Q73093135 |
| | Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 | Q73935037 |
| | Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1 | Q73944454 |
| | Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma | Q74229290 |
| | Neuropilin-1 is a placenta growth factor-2 receptor | Q77126823 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| | endothelium | Q111140 |
| | prostate neoplasm | Q56014511 |
| P304 | page(s) | 651-9 | |
| P577 | publication date | 2001-08-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype | |
| P478 | volume | 159 | |